Similar Papers

Paper Title
Journal
Date
Author
Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience
Yucai Wang ... Wei Ding
Blood | VOL. 136
Yucai Wang, et. al.Yucai Wang ... Wei Ding
05 Nov 2020
Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
Lindsey E Roeker ...
Blood | VOL. 132
Lindsey E Roeker, et. al.Lindsey E Roeker ...
29 Nov 2018
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Alessandra Tedeschi ... Xavier C Badoux
Blood | VOL. 134
Alessandra Tedeschi, et. al.Alessandra Tedeschi ... Xavier C Badoux
13 Nov 2019
Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors
Meghan C Thompson ... Anthony R Mato
Blood | VOL. 138
Meghan C Thompson, et. al.Meghan C Thompson ... Anthony R Mato
05 Nov 2021
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
Christine E Ryan ... Matthew S Davids
HemaSphere | VOL. 9
Christine E Ryan, et. al.Christine E Ryan ... Matthew S Davids
01 Jan 2025
"Low-risk" myelodysplastic neoplasm (MDS): Time for a name change?
Shoshana Burke ... Stephen P Hibbs
HemaSphere | VOL. 9
Shoshana Burke, et. al.Shoshana Burke ... Stephen P Hibbs
01 Jan 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Maximilian Merz ... Nico Gagelmann
HemaSphere | VOL. 9
Maximilian Merz, et. al.Maximilian Merz ... Nico Gagelmann
01 Jan 2025
Issue Information
-
HemaSphere | VOL. 9
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.